Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear.
The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
RSV causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon.
ESWI Airborne: Burden of Disease
Burden of disease - A focus on acute respiratory viruses in older adults
Why should older adults be particularly careful of acute respiratory viruses? What are risk factors for adverse outcomes? Why is RSV typically under-diagnosed in adults compared with flu and what are some of the long-term impacts?
Policy & Recommendations
European Commission authorises first vaccine to protect older adults from RSV infection
The EC has authorised Arexvy, the first vaccine to protect adults aged 60 years and older, against RSV. This decision marks an important step and has been particularly awaited in light of the increased RSV infections in the EU last winter.
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
RSV infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
Estimation of the number of RSV-associated hospitalisations in adults in the European Union
RSV is a major cause of lower respiratory tract infections in older adults. Estimating RSV- associated hospitalisation is critical for planning RSV-related healthcare needs for the ageing population across Europe.
The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design
After a 1960s RSV vaccine was found to enhance disease in previously unexposed infants, development was put on hold. But structure-based design has led to effective RSV vaccines that now await approval.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years
Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
This article assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials.
Rate of Hospitalizations and Mortality of Respiratory Syncytial Virus Infection Compared to Influenza in Older People: A Systematic Review and Meta-Analysis
Since the data regarding the impact of RSV are still limited for older people, the aim of this systematic review and meta-analysis is to compare the rate of hospitalization and mortality between RSV and influenza in this population.
Respiratory Syncytial Virus Protects Bystander Cells against Influenza A Virus Infection by Triggering Secretion of Type I and Type III Interferons
We observed the interference between two prevalent respiratory viruses, respiratory syncytial virus (RSV) and influenza A virus (IAV) (H1N1), and characterized its molecular underpinnings in alveolar epithelial cells (A549).
The Health System Burden of RSV in Europe
European Health Management Association's (EHMA) white paper on the health system burden of the Respiratory syncytial virus (RSV) in Europe.